Development of dual toxoid-loaded layersomes for complete immunostimulatory response following peroral administration

Nanomedicine

Volumn 10, Issue 7, 2015, Pages 1077-1091

  Harde, Harshad ^a   Siddhapura, Krupa ^a   Agrawal, Ashish Kumar ^a   Jain, Sanyog ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

layersomes; mucosal immunity; oral delivery; toxoids; vaccine

Indexed keywords

BOVINE SERUM ALBUMIN; DUAL ANTIGEN VACCINE; GAMMA INTERFERON; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 2; LAYERSOME; LIPOSOME; POLYELECTROLYTE; TETANUS TOXOID; UNCLASSIFIED DRUG; VACCINE; DIPHTHERIA TOXOID; IMMUNOGLOBULIN G;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BIOLOGICAL ACTIVITY; BODY FLUID; CACO 2 CELL LINE; CONFORMATION; CONTROLLED STUDY; FEMALE; IMMUNIZATION; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOSTIMULATION; IN VITRO STUDY; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; ZETA POTENTIAL; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CELL LINE; CHEMISTRY; DIPHTHERIA; HUMAN; IMMUNOLOGY; ORAL DRUG ADMINISTRATION; TETANUS;

ADMINISTRATION, ORAL; ANIMALS; CACO-2 CELLS; CELL LINE; DIPHTHERIA; DIPHTHERIA TOXOID; FEMALE; HUMANS; IMMUNIZATION; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INTERFERON-GAMMA; INTERLEUKIN-2; LIPOSOMES; MICE; MICE, INBRED BALB C; TETANUS; TETANUS TOXOID;

EID: 84929091401     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.14.177     Document Type: Article

References (35)

1. Jain S, Khomane K, Jain AK, Dani P. Nanocarriers for transmucosal vaccine delivery. Curr. Nanosci. 7(2), 160-177 (2011).
2. Chen X, Fernando GJ, Crichton ML et al. Improving the reach of vaccines to low-resource regions, with a needle-free vaccine delivery device and long-term thermostabilization. J. Control. Release 152(3), 349-355 (2011).
3. Fahmy TM, Demento SL, Caplan MJ, Mellman I, Saltzman WM. Design opportunities for actively targeted nanoparticle vaccines. Nanomedicine 3(3), 343-355 (2008).
4. Garinot M, Fievez V, Pourcelle V et al. PEGylated PLGAbased nanoparticles targeting M cells for oral vaccination. J. Control. Release 120(3), 195-204 (2007).
5. Van Der Lubben IM, Kersten G, Fretz MM et al. Chitosan microparticles for mucosal vaccination against diphtheria: oral and nasal efficacy studies in mice. Vaccine 21(13), 1400-1408 (2003).
6. Bowman K, Leong KW. Chitosan nanoparticles for oral drug and gene delivery. Int. J. Nanomed. 1(2), 117-128 (2006).
7. Jain S, Harde H, Indulkar A, Agrawal AK. Improved stability and immunological potential of tetanus toxoid containing surface engineered bilosomes following oral administration. Nanomedicine 10(2), 431-440 (2014)
8. Jain S, Indulkar A, Harde H, Agrawal AK. Oral mucosal immunization using glucomannosylated bilosomes. J. Biomed. Nanotechnol. 10(6), 932-947 (2014).
9. Agrawal AK, Harde HP, Thanki K, Jain S. Improved stability and antidiabetic potential of insulin containing folic acid functionalized polymer stabilized multilayered liposomes following oral administration. Biomacromolecules 15(1), 350-360 (2014).
10. Jain S, Kumar D, Swarnakar NK, Thanki K. Polyelectrolyte stabilized multilayered liposomes for oral delivery of paclitaxel. Biomaterials 33(28), 6758-6768 (2012).
11. Harde H, Agrawal AK, Jain S. Trilateral '3P' mechanics of stabilized layersomes technology for efficient oral immunization. J. Biomed. Nanotechnol. 11(3), 363-381 (2015)
12. Jain S, Patil SR, Swarnakar NK, Agrawal AK. Oral delivery of doxorubicin using novel polyelectrolytes stabilized liposomes (layersomes). Mol. Pharmaceutics 9(9), 2626-2635 (2012).
13. Jelvehgari M, Zakeri-Milani P, Siahi-Shadbad MR et al. Development of pH-sensitive insulin nanoparticles using Eudragit L100-55 and chitosan with different molecular weights. AAPS PharmSciTech. 11(3), 1237-1242 (2010).
14. Jain S, Rathi VV, Jain AK, Das M, Godugu C. Folatedecorated PLGA nanoparticles as a rationally designed vehicle for the oral delivery of insulin. Nanomedicine 7(9), 1311-1337 (2012).
15. Lyng J, Bentzon MW. The quantitative estimation of diphtheria and tetanus toxoids. 1. The flocculation test and the Lf-unit. J. Biol. Stand. 15(1), 27-37 (1987).
16. Sarmento B, Ribeiro A, Veiga F et al. Alginate/chitosan nanoparticles are effective for oral insulin delivery. Pharm. Res. 24(12), 2198-2206 (2007).
17. Jain AK, Thanki K, Jain S. Co-encapsulation of tamoxifen and quercetin in polymeric nanoparticles: implications on oral Bioavailability, antitumor efficacy, and drug-Induced toxicity. Mol. Pharmaceutics 10(9), 3459-3474 (2013).
18. Sarti F, Perera G, Hintzen F et al. In vivo evidence of oral vaccination with PLGA nanoparticles containing the immunostimulant monophosphoryl lipid A. Biomaterials 32(16), 4052-4057 (2011).
19. Harde H, Agrawal AK, Jain S. Development of stabilized glucomannosylated chitosan nanoparticles using tandem crosslinking method for oral vaccine delivery. Nanomedicine 9(16), 2511-2529 (2015).
20. Singh M, Li X-M, Wang H et al. Immunogenicity and protection in small-animal models with controlled-release tetanus toxoid microparticles as a single-dose vaccine. Infect. Immun. 65(5), 1716-1721 (1997).
21. Men Y, Thomasin C, Merkle HP, Gander B, Corradin G. A single administration of tetanus toxoid in biodegradable microspheres elicits T cell and antibody responses similar or superior to those obtained with aluminum hydroxide. Vaccine 13(7), 683-689 (1995).
22. Harde H, Agrawal AK, Jain S. Tetanus toxoids loaded glucomannosylated chitosan based nanohoming vaccine adjuvant with improved oral stability and immunostimulatory response. Pharm. Res. 32(1), 122-134 (2015).
23. Zhang Y, Huo M, Zhou J et al. DDSolver: an add-in program for modeling and comparison of drug dissolution profiles. AAPS J. 12(3), 263-271 (2010).
24. Abdelwahed W, Degobert G, Stainmesse S, Fessi H. Freezedrying of nanoparticles: formulation, process and storage considerations. Adv. Drug Del. Rev. 58(15), 1688-1713 (2006).
25. Thomasin C, Corradin G, Men Y, Merkle HP, Gander B. Tetanus toxoid and synthetic malaria antigen containing poly (lactide)/poly (lactide-co-glycolide) microspheres: importance of polymer degradation and antigen release for immune response. J. Control. Release 41(1), 131-145 (1996).
26. Harde H, Das M, Jain S. Solid lipid nanoparticles: an oral bioavailability enhancer vehicle. Exp. Opin. Drug Del. 8(11), 1407-1424 (2011)
27. Mathiowitz E, Jacob JS, Jong YS et al. Biologically erodable microspheres as potential oral drug delivery systems. Nature 386(6623), 410-414 (1997).
28. Des Rieux A, Fievez V, Garinot M, Schneider YJ, Préat V. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J. Control. Release 116(1), 1-27 (2006).
29. Tacken PJ, De Vries IJM, Torensma R, Figdor CG. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat. Rev. Immunol. 7(10), 790-802 (2007).
30. Tiwari S, Agrawal GP, Vyas SP. Molecular basis of the mucosal immune system: from fundamental concepts to advances in liposome-based vaccines. Nanomedicine 5(10), 1617-1640 (2010).
31. Ogra PL, Faden H, Welliver RC. Vaccination strategies for mucosal immune responses. Clin. Microb. Rev. 14(2), 430-445 (2001).
32. Mackay IR, Rosen FS, Ada G. Vaccines and vaccination. N. Engl. J. Med. 345(14), 1042-1053 (2001).
33. Walker WA. Host defense mechanisms in the gastrointestinal tract. Pediatrics 57, 901-907 (1976).
34. Borrow R, Balmer P, Roper M. The Immunological Basis for Immunization Series. Module 3: Tetanus. Department of Immunization, Vaccines and Biologicals. World Health Organization, Geneva, Switzerland, 8-10 (2006).
35. Plotkin SA. Correlates of protection induced by vaccination. Clin. Vaccine Immunol. 17(7), 1055-1065 (2010).